bg-img9.jpg
8.jpg
The Evolution of Public Health Research: Heart Disease, Part 1

How a Radio Game Show and a Town in Massachusetts Invented Biobanking and Redefined Public Health Research

Topic: Public Health Research, The Evolution of Pu..........

Expanding our Global Footprint: Supporting Cell and Gene Therapy in Japan

As I mentioned in my previous blog, favorable regulations in Japan are impacting cell therapy clinical trials conducted by the biopharmaceutical industry on a global scale.  To meet this increasing demand Fisher BioServices has expanded our cryogenic service capabilities in Tokyo, Japan.  This expansion enables our customers to seamlessly conduct clinical trials across multiple geographies and provide patients around the world with access to life changing therapies. 

Topic: Cell Therapy Solutions, Content: Blog

Cell Therapy Clinical Trials and the Mad Dash to Japan

When Shinzo Abe was re-elected as Japan's Prime Minister he aggressively embarked on a challenge to revive Japan's struggling economy. With the introduction of Abenomics, an economic policy that includes "three arrows" of fiscal stimulus, monetary easing, and structural reforms, the ball was set in motion to redefine Japan's standings within the global market.

Topic: Cell Therapy Solutions, Content: Blog

Controlling Preanalytical Variability in Biospecimen Collections

Large, well-designed population studies and the interrelationships they reveal are the backbone of public health and serve as a foundation for medical research. The health and lifestyle information of participants, collected via questionnaire and linked to their biospecimen samples, allow investigators to examine the intricate relationships between genetics, physiology, behavior, environment, and disease.

Content: eBook, Topic: Public Health Research

CAR T-Cell Therapy: High Risk, High Reward Part 2

As discussed in Part 1 of this blog series, Chimeric Antigen Receptor (CAR) T-cells are having an incredible impact on the cell therapy industry.  However, despite the many success stories, there are also several items that require consideration if we are to truly harness the potential of this type of therapy.  Let’s begin by exploring some of the unresolved questions and issues surrounding CAR T-cell therapy.

Topic: Cell Therapy Solutions, Content: Blog

CAR T-Cell Therapy: High Risk, High Reward Part 1

Of all the advances in medicine recently, cellular therapy is perhaps the most intriguing. It is a fast-paced, ever changing market that tests the boundaries of innovation and has forever changed the way we approach certain diseases. However, this type of medical discovery comes with its fair share of risk, but when all goes according to plan, the rewards can be great.

Topic: Cell Therapy Solutions, Content: Blog

European Biobank Week: Biobanking for health innovation

Biobanks serve a common goal: to improve understanding of patients, diseases and health; and to deliver the best individualized care. Sample quality is paramount to achieving that goal. Without confidence in the integrity of biosamples, there can be no confidence in the results.  To support this effort, we are pleased to announce our participation at the upcoming European Biobank Week (EBW) in Vienna, Austria.

Topic: Biobanking and Biorepository, Content: Blog

Shooting for the Moon: A New Cancer Immunotherapy Initiative

In 1962, President John F. Kennedy electrified the nation when he declared our intent to send a man to the moon. This year, President Obama declared a new “shoot for the moon” endeavor: to find an effective immunotherapy treatment for cancer by the year 2020.

Topic: Cell Therapy Solutions, Content: Blog

Expansion Cohort Clinical Trials and Your Cryogenic Supply Chain

One advantage to the traditional phase 1, 2, and 3 format of clinical trials is that it allows reasonable forecasting with regard to the clinical supply chain. This phase 1-2-3 format is rapidly changing, however, especially with regard to biological therapies, as more and more clinical trials include expansion cohorts. If you are planning clinical trials for a cell-based therapy that must be maintained in liquid nitrogen, and may potentially take the expansion cohort route, you should consider the impact on your distribution capabilities as soon as possible.

Topic: Cold-Chain Logistics, Topic: Cell Therapy S..........

Factors Affecting Participation Rates in Population-Based Biobanking

A systematic review and meta-analysis of baseline participation rates and their determinants performed by van Zon et al. (2016) found that recruitment methods and design affect participation rates.1 Population-based biobanks are essential platforms for innovation and knowledge generation in health care research, specifically in regards to how we prevent, treat and cure widespread diseases. Therefore, willingness to participate from the population is pivotal if biobank studies are to continue to contribute to public health research.

Topic: Biobanking and Biorepository, Topic: Public..........

The Evolution of Public Health Research: HIV/AIDS

No one reading this blog was alive when John Snow created his famed cholera map of Soho, or when Robert Koch discovered M. tuberculosis. Many of us weren’t alive, much less paying attention to scientific studies, when the Framingham Heart Study was published to link cigarettes to lung cancer. But there’s one epidemic that everyone should be familiar with. One that was extensively covered in the media, that aspiring children dreamed of curing, that has inspired so many award-winning movies, that was declared a threat to national security.

Topic: Public Health Research, The Evolution of Pu..........

How to Maintain Sample Integrity During Sample Transfer

The data that lies within your biospecimen collections holds the keys to your research and, as we’ve discussed previously, it’s imperative to maintain proper temperature to ensure sample integrity.  This is a challenge ordinarily, but even more so when attempting to transfer samples.

Topic: Biobanking and Biorepository, Topic: Public..........